Cost-Effectiveness Analysis of Extended-Release Formulations of Oxybutynin and Tolterodine for the Management of Urge Incontinence

PharmacoEconomics - Tập 22 Số 16 - Trang 1047-1059 - 2004
Dyfrig Hughes1, Dominique Dubois2
1Centre for the Economics of Health, IMSCaR, University of Wales, Wales, UK
2Johnson & Johnson Pharmaceutical Services LLC, Beerse, Belgium

Tóm tắt

Từ khóa


Tài liệu tham khảo

Hagglund, 2001, Acta Obstet Gynecol Scand, 80, 1051

Bemelmans, 2000, Eur Urol, 37, 709, 10.1159/000020222

Versi, 2000, Obstet Gynecol, 95, 718

Harvey, 2001, Am J Obstet Gynecol, 185, 56, 10.1067/mob.2001.116371

Appell, 2001, Mayo Clin Proc, 76, 358, 10.1016/S0025-6196(11)62382-3

Van Kerrebroeck, 2001, Urology, 57, 414, 10.1016/S0090-4295(00)01113-4

Anderson, 1999, J Urol, 161, 1809, 10.1016/S0022-5347(05)68810-6

Desgagne, 1999, Value Health, 2, 452, 10.1046/j.1524-4733.1999.26005.x

Garnett, 2003, J Urol, 169, 843, 10.1097/01.ju.0000050305.05345.40

Sussman, 2002, Curr Med Res Opin, 18, 177, 10.1185/030079902125000570

Langman, 2001, Pharmacoepidemiol Drug Saf, 10, 517, 10.1002/pds.653

Gupta, 1999, Clin Pharmacol Ther, 65, 672, 10.1016/S0009-9236(99)90089-9

OBrien, 2001, Clin Ther, 23, 2038, 10.1016/S0149-2918(01)80156-9

Kobelt, 1998, Neurourol Urodyn, 17, 599, 10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J

Arikian, 2000, Manag Care Interface, 13, 88

Roberts, 1998, J Am Geriatr Soc, 46, 467, 10.1111/j.1532-5415.1998.tb02468.x

Roe, 1999, Int J Nur Stud, 36, 245, 10.1016/S0020-7489(99)00020-6

Hughes, 2001, Health Econ, 10, 601, 10.1002/hec.609